Please Wait
Applying Filters...
menu
    • menu
    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-24

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Menu

    Neflamapimod

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    CervoMed Reports 2024 Financial Results and Corporate Updates
    CervoMed Reports 2024 Financial Results and Corporate Updates

    17 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/17/3043647/0/en/CervoMed-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Provides-Corporate-Updates.html

    GLOBENEWSWIRE
    17 Mar 2025
    Share Share
    CervoMed Updates On Neflamapimod DLB At Lewy Body Conference
    CervoMed Updates On Neflamapimod DLB At Lewy Body Conference

    31 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/31/3018769/0/en/CervoMed-Provides-Update-on-Neflamapimod-DLB-Program-as-Part-of-Presentation-at-the-8th-International-Lewy-Body-Dementia-Conference.html

    GLOBENEWSWIRE
    31 Jan 2025
    Share Share
    CervoMed Gets Orphan Drug Status for Neflamapimod in FTD
    CervoMed Gets Orphan Drug Status for Neflamapimod in FTD

    27 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/27/2988107/0/en/CervoMed-Announces-Orphan-Drug-Designation-Granted-to-Neflamapimod-by-U-S-Food-and-Drug-Administration-for-the-Treatment-of-Frontotemporal-Dementia.html

    GLOBENEWSWIRE
    27 Nov 2024
    Share Share
    CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup
    CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

    08 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/08/2977725/0/en/CervoMed-Awarded-the-Prix-Galien-USA-2024-Prize-for-Best-Startup.html

    GLOBENEWSWIRE
    08 Nov 2024
    Share Share
    CervoMed Announces Last Patient Visit In Phase 2b RewinD-LB Trial
    CervoMed Announces Last Patient Visit In Phase 2b RewinD-LB Trial

    15 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/15/2963137/0/en/CervoMed-Announces-Last-Patient-Last-Visit-in-Phase-2b-RewinD-LB-Trial-of-Neflamapimod-for-the-Treatment-of-Early-Stage-Dementia-with-Lewy-Bodies-DLB.html

    GLOBENEWSWIRE
    15 Oct 2024
    Share Share
    CervoMed To Present Neflamapimod Biomarker Data In DLB At AAIC 2024
    CervoMed To Present Neflamapimod Biomarker Data In DLB At AAIC 2024

    29 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/29/2920251/0/en/CervoMed-Announces-Presentation-at-AAIC-2024-on-Plasma-Biomarker-Data-That-Are-Consistent-with-Neflamapimod-Impacting-the-Underlying-Disease-Process-in-Patients-with-Dementia-with-.html

    GLOBENEWSWIRE
    29 Jul 2024
    Share Share